ReviewGene therapy2021
Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics.
Review in Gene therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Current and emerging molecular diagnostic approaches in the detection of human parasites.Parasitology research · 2026Review
- Favipiravir as a potent inhibitor of Newcastle disease virus:Veterinary world · 2025Article
- Cardiovascular abnormalities of long-COVID syndrome: Pathogenic basis and potential strategy for treatment and rehabilitation.Sports medicine and health science · 2024Review
- Targeting and engineering long non-coding RNAs for cancer therapy.Nature reviews. Genetics · 2024Review
- Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects.Biosafety and health · 2023Review
- A Review on Advanced CRISPR-Based Genome-Editing Tools: Base Editing and Prime Editing.Molecular biotechnology · 2023Review
- World Health Organization's first-ever release of a fungal priority pathogens list: A reply action proposal for the prevention and treatment of fungal pathogens.Eco-Environment & Health · 2023Article
- Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2023Review
- Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications.Pharmaceutics · 2023Review
- Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis.Frontiers in genetics · 2023Review
- Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection.International journal of molecular sciences · 2022Review
- RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges.Cellular & molecular biology letters · 2022Review
- Review
- Severe Acute Respiratory Syndrome Type 2-Causing Coronavirus: Variants and Preventive Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.Analytical and bioanalytical chemistry · 2022Review
- Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm.Journal of personalized medicine · 2022Review
- Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.International journal of molecular sciences · 2022Review
- Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.Nucleic acids research · 2022Article
- Development and application of ribonucleic acid therapy strategies against COVID-19.International journal of biological sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9-13, Lancet 2020;395:497-506, N. Engl J Med 2020a;382:1199-207, Nature 2020;579:270-3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265-9, N. Engl J Med 2020;382:727-33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444-8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1-18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727-33, MedRxiv 2020a, Turkish J Biol 2020;44:192-202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.